CandidPharm · Ningbo Candid Pharmaceutical Co., Ltd. · 宁波嘉安药业有限公司
CATEGORY E · CP-RUXO-01Intermediate

(R)-3-cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile

(R)-3-环戊基-3-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-1H-吡唑-1-基)丙腈
CAS Registry No.
1146629-84-6
Related API
Ruxolitinib
Molecular Weight
315.2
Product Type
Intermediate

Identification & Structure

Chemical structure of (R)-3-cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile
2D Structure

B1(OC(C(O1)(C)C)(C)C)C2=CN(N=C2)[C@H](CC#N)C3CCCC3

Product CodeCP-RUXO-01
Product TypeIntermediate
CAS Number1146629-84-6
Molecular FormulaC17H26BN3O2
Molecular Weight315.2
IUPAC Name(3R)-3-cyclopentyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propanenitrile
SMILESB1(OC(C(O1)(C)C)(C)C)C2=CN(N=C2)[C@H](CC#N)C3CCCC3
InChIKeyLJZLJWDLFHJEOC-OAHLLOKOSA-N
PubChem CID58221004
Quality ParametersRequest current specification and available batch documentation

Related API

Listed in our catalog as an intermediate related to Ruxolitinib.

Specifications and available documentation are reviewed against your project requirements. Availability and lead time are confirmed for each enquiry, taking current stock and production schedules into account.

Direct Inquiries

Request a Quote & Documents

Tell us the quantity, specification and destination. We will reply by email with pricing, lead time and the documents available.

· We will reply by email
· Mutual NDA available on request

Documents on Request

Request current specification and available batch documentation. We will confirm which TDS, SDS, CoA and analytical materials can be shared for this product.

Patent Notice

Supply is reviewed against the destination, patent status and intended use. Products are not offered where the transaction would infringe valid patents or supplementary protection certificates. Where applicable, regulatory-development activities may fall within the Bolar exemption under Article 10(6) of EU Directive 2001/83/EC, as amended by Directive 2004/27/EC, or 35 U.S.C. § 271(e)(1). These provisions have specific conditions; research use alone does not establish an exemption. Buyers must confirm applicable requirements for their jurisdiction and project before ordering. Commercial supply in protected territories requires an applicable legal basis.